Acme Formulation

What Acme Formulation does

Acme Formulation Pvt. Ltd. is an India-based pharmaceutical contract manufacturing organization (CMO) operating from a 170,000 sq. ft. facility in Nalagarh, District Solan, Himachal Pradesh, with a corporate office in Mohali. Established in 2004 as part of the Acme Group (which also comprises Acme Generics, Immacule Lifesciences, and Veritas Research), the company specializes in Oral Solid Dosage (OSD) manufacturing—producing general tablets, capsules, and oral contraceptives, with a dedicated Hormonal Block for female sex hormone tablets (1 billion tablet capacity annually). Total OSD capacity stands at 3 billion tablets and 1 billion capsules per year. Core manufacturing capabilities span rapid mixer granulation (150L-600L), fluid bed drying, multi-station compression (up to 200,000 tablets/hour), automated coating, AF-40T capsule filling (40,000 capsules/hour), and an 11-line packaging operation including blister, strip, and bottle packing.

The company operates a B2B contract manufacturing model, serving top Indian and global multinational pharmaceutical companies across regulated and emerging markets. Revenue is generated through transaction-fee manufacturing contracts, professional services for R&D via Veritas Research (50+ scientists), licensing/technology-transfer arrangements, and regulatory filing/registration support. The company holds approvals from USFDA (with zero 483 observations), EU-GMP, WHO Geneva, UK MHRA, ANVISA, INVIMA Colombia, TGA Australia, Health Canada, and PICS, with 38 ANDA approvals and 18-19 filings under review, targeting 50+ ANDA approvals by 2025. Distribution spans 75+ countries across Europe, North America, South America, Africa, ANZ, Asia, CIS, and the UK, covering an estimated 69% of global geography.

Acme Formulation is positioning itself as a fully integrated CDMO, evidenced by a USD 100 million sterile-capacity expansion announced for 2024-2025 covering injectables, ophthalmics, pre-filled syringes, and cartridges, complementing the existing OSD core. The business is private, with PAG (Pacific Alliance Group) as a private equity investor since October 2021 and founder Viral Shah (MS Chemical Engineering, USC) serving as CEO and Managing Director since April 2005. Go-to-market is enterprise field sales, supplemented by participation in industry events such as CPHI Milan 2024.

Name

Acme Formulation

Legal name

Acme Formulation Pvt. Ltd.

Website

https://acmegenerics.in

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Acme Formulation is an India-based pharmaceutical CMO specializing in oral solid dosage manufacturing (tablets, capsules, oral contraceptives, hormonal products), serving top Indian and global pharma companies with multi-jurisdictional regulatory approvals across 75+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Pharmaceutical contract manufacturing
• Oral solid dosage
• CDMO services
• Hormonal tablet manufacturing
• Generic drug development

Headquarters

HQ city

Solan

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services (CMO): Provides contract manufacturing services to pharmaceutical companies for finished products including tablets, capsules, and oral contraceptives. Revenue generated through manufacturing fees based on production volume and specifications.
2. Contract Research & Development: R&D services including generic drug development, innovative generics, and drug delivery technologies for pharmaceutical clients.
3. Finished Product Filing & Registration: Regulatory filing services for product registration across different markets.
4. Licensing & Technology Transfers: Technology transfer services and licensing arrangements for pharmaceutical manufacturing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Acme Formulation is a pharmaceutical contract manufacturing organization (CMO/CDMO) providing fully integrated manufacturing and development solutions for oral solid dosage forms. The company manufactures general tablets, capsules, oral contraceptives, and hormonal tablets (including female sex hormones) for Indian and global pharmaceutical companies, supported by in-house regulatory filing, R&D, technology transfer, and co-development services.

Product overview

Acme Formulation is part of the Acme Group, a pharmaceutical contract manufacturing organization (CMO) providing integrated manufacturing and development solutions. The company operates as a single manufacturing facility specializing in Oral Solid Dosage (OSD) forms including tablets, capsules, and oral contraceptives. The portfolio includes: (1) general tablet/capsule manufacturing with 3 billion tablet and 1 billion capsule capacity, (2) hormonal products with 1 billion tablet capacity from dedicated Hormone Block, (3) comprehensive manufacturing capabilities across granulation, compression, coating, capsule filling, and packaging. Services include CMO contract manufacturing, regulatory filing/registration, R&D through Veritas Research, co-development, and technology licensing. The company operates a 170,000 sq. ft. facility in Nalagarh, India with EU-GMP, WHO Geneva, and INVIMA approvals.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Manufacturing (CMO) Services

Quantifiable outcome

• 38 ANDA approvals achieved
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Syngene International: Indian CRO/CDMO providing integrated discovery, development, and manufacturing services to global pharma. Comparable as an India-based contract services peer with similar customer profile and B2B model.
• Strides Pharma Science: Indian pharmaceutical company with regulated finished dosage manufacturing (OSD, soft gels, sterile) and global generic markets focus. Comparable in customer type, regulatory footprint, and dosage form coverage.
• Granules India: Indian pharmaceutical manufacturer focused on high-volume generic OSD APIs and finished doses, exporting globally. Comparable scale and customer type to Acme Formulation's OSD CMO offering.
• Aurobindo Pharma: Large Indian pharmaceutical company with significant generic OSD manufacturing and a US-focused generics franchise with hundreds of ANDA approvals. Highly comparable to Acme Formulation's generic OSD CMO/CDMO model serving global markets.
• Jubilant Pharmova: Indian pharma company with CDMO operations across sterile injectables, OSD, and APIs, plus a radiopharma business. Comparable CDMO breadth and customer base to Acme Group's multi-entity platform.
• Dishman Carbogen Amcis: India-based CDMO with API and drug product manufacturing capabilities serving global pharma. Directly comparable as an Indian-headquartered contract manufacturer with regulated-market approvals.
• MSN Laboratories: Indian pharmaceutical company with API and finished dose manufacturing (including OSD and injectables) and a growing CDMO business. Comparable in size, customer mix, and regulated-market focus.
• Piramal Pharma Solutions: India-headquartered integrated CDMO offering drug substance and drug product development across multiple dosage forms including OSD and sterile injectables. Directly comparable to Acme Group's CDMO positioning across Acme Formulation and Immacule.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Global CDMO via the Patheon brand offering drug substance, drug product, and clinical/commercial manufacturing services. Comparable as a broad incumbent competing for the same large pharma contract manufacturing work.
• Catalent: Global, large-scale CDMO with deep capabilities in OSD, sterile, and biologics across multiple geographies. Comparable as a much larger incumbent operating in the same contract manufacturing and development space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=yYVplv7vV-g
• LinkedInlinkedin.com/company/acme-formulation

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acme Formulation